FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955062175> ?p ?o ?g. }

• W2955062175 abstract "Introduction: Anaplastic thyroid cancer (ATC) is a rare refractory disease, found in 1-3% of thyroid cancer. Because of its highly malignant potential, patients often become lethal within 6 months, nevertheless for intensive multimodal therapies. Recent observations indicated the strong efficacy of multi-kinase inhibitor to control disease progression of ATC. Frequent BRAF mutation (40-60%) in tumors of ATC was reported in Japan, indicating BRAF gene alteration as possible molecular target. Moreover, the secretions of VEGF were often found in ATC cell lines, suggesting the important role of VEGF-mediated tumor neo-vascularization in the aggressive progression of ATC. We, thus, examined the antitumor effect of Sorafenib, a multi-kinase inhibitor demonstrating its effect by inhibiting both BRAF and VEGF signal. Materials & Methods: Human ATC cell lines having four different gene mutations were used (OCUT-4; BRAF mutation, OCUT-6, ACT-1; NRAS mutation, OCUT-2; BRAS and PI3KCA mutation). The effect of Sorafenib on cellular viability was evaluated by MTT assay. In order to investigate the mechanism of cellular damage by Sorafenib, cell cycle was evaluated by flowcytometry, and the signal transduction of RAF/MEK pathway was examined by Western blotting. The amount of VEGF secretion from cells was measured by ELISA. Expression of VEGF-receptor in cells was evaluated by Western blotting. Furthermore, the effects of Sorafenib on human vascular endothelial cells were investigated by recruiting HUVEC (Kurabo, Japan) stimulated with VEGF and conditioned medium of the cancer cells. Results: The effect of Sorafenib appears most strongly in OCUT-4 cell with BRAF mutation compared with other cell lines. However, the impairment of cellular viability was shown at relatively high concentration (>100 nM). OCUT-4 showed G1 phase arrest by Sorafenib exposure. The specific effect of BRAF inhibition was confirmed by the suppression of MEK and ERK phosphorylation in OCUT-4. The suppression was not observed in OCUT-6, a cell line with NRAS mutation. The paradoxical increase of MEK phosphorylation was found in this cell line, instead. Every cell line secreted different amount of VEGF, and the proliferation of HUVEC was stimulated by their conditioned mediums similarly as by VEGF. The stimulation of proliferation was suppressed both by anti-VEGF antibody and Sorafenib. Discussion: In the present study, we clearly demonstrated that Sorafenib inhibits growth of human vascular endothelium mediated by VEGF secretion from cancer cells, as well as direct cell cycle arrest on ATC cells. A high concentration of Sorafenib may be needed to show inhibition on the RAF/MEK pathway. Furthermore, the inhibition of the pathway was not effective when additional growth stimulatory pathway than RAF was activated as in case of OCUT-2, or RAS gene were mutated. However, in any case, cancer cell growth mediated by autocrine system was inhibited clearly by Sorafenib. Citation Format: SAE ISHIHARA. Mechanism of antitumor effect of Sorafenib in anaplastic thyroid cancer cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1025." @default.
• W2955062175 created "2019-07-12" @default.
• W2955062175 creator A5065433903 @default.
• W2955062175 date "2019-07-01" @default.
• W2955062175 modified "2023-09-27" @default.
• W2955062175 title "Abstract 1025: Mechanism of antitumor effect of Sorafenib in anaplastic thyroid cancer cell lines" @default.
• W2955062175 doi "https://doi.org/10.1158/1538-7445.sabcs18-1025" @default.
• W2955062175 hasPublicationYear "2019" @default.
• W2955062175 type Work @default.
• W2955062175 sameAs 2955062175 @default.
• W2955062175 citedByCount "0" @default.
• W2955062175 crossrefType "proceedings-article" @default.
• W2955062175 hasAuthorship W2955062175A5065433903 @default.
• W2955062175 hasConcept C121608353 @default.
• W2955062175 hasConcept C126322002 @default.
• W2955062175 hasConcept C2778019345 @default.
• W2955062175 hasConcept C2778695046 @default.
• W2955062175 hasConcept C2779761222 @default.
• W2955062175 hasConcept C2780256643 @default.
• W2955062175 hasConcept C2780394083 @default.
• W2955062175 hasConcept C502942594 @default.
• W2955062175 hasConcept C54355233 @default.
• W2955062175 hasConcept C62112901 @default.
• W2955062175 hasConcept C71924100 @default.
• W2955062175 hasConcept C81885089 @default.
• W2955062175 hasConcept C86803240 @default.
• W2955062175 hasConceptScore W2955062175C121608353 @default.
• W2955062175 hasConceptScore W2955062175C126322002 @default.
• W2955062175 hasConceptScore W2955062175C2778019345 @default.
• W2955062175 hasConceptScore W2955062175C2778695046 @default.
• W2955062175 hasConceptScore W2955062175C2779761222 @default.
• W2955062175 hasConceptScore W2955062175C2780256643 @default.
• W2955062175 hasConceptScore W2955062175C2780394083 @default.
• W2955062175 hasConceptScore W2955062175C502942594 @default.
• W2955062175 hasConceptScore W2955062175C54355233 @default.
• W2955062175 hasConceptScore W2955062175C62112901 @default.
• W2955062175 hasConceptScore W2955062175C71924100 @default.
• W2955062175 hasConceptScore W2955062175C81885089 @default.
• W2955062175 hasConceptScore W2955062175C86803240 @default.
• W2955062175 hasLocation W29550621751 @default.
• W2955062175 hasOpenAccess W2955062175 @default.
• W2955062175 hasPrimaryLocation W29550621751 @default.
• W2955062175 hasRelatedWork W1417458945 @default.
• W2955062175 hasRelatedWork W1529789444 @default.
• W2955062175 hasRelatedWork W1530665180 @default.
• W2955062175 hasRelatedWork W1601647392 @default.
• W2955062175 hasRelatedWork W2055695980 @default.
• W2955062175 hasRelatedWork W2079369175 @default.
• W2955062175 hasRelatedWork W2080527870 @default.
• W2955062175 hasRelatedWork W2097025421 @default.
• W2955062175 hasRelatedWork W2163885490 @default.
• W2955062175 hasRelatedWork W2282214838 @default.
• W2955062175 hasRelatedWork W2315283981 @default.
• W2955062175 hasRelatedWork W2331761697 @default.
• W2955062175 hasRelatedWork W2529221584 @default.
• W2955062175 hasRelatedWork W2791811230 @default.
• W2955062175 hasRelatedWork W2925963101 @default.
• W2955062175 hasRelatedWork W2979572678 @default.
• W2955062175 hasRelatedWork W3120683986 @default.
• W2955062175 hasRelatedWork W3143273383 @default.
• W2955062175 hasRelatedWork W3182895314 @default.
• W2955062175 hasRelatedWork W631169674 @default.
• W2955062175 isParatext "false" @default.
• W2955062175 isRetracted "false" @default.
• W2955062175 magId "2955062175" @default.
• W2955062175 workType "article" @default.